4-苯基哌啶-4-甲酰胺单盐酸盐 | 59083-35-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-苯基哌啶-4-甲酰胺单盐酸盐
• 英文名称: 4-phenyl-piperidine-4-carboxylic acid amide hydrochloride
• 英文别名: 4-phenylpiperidine-4-carboxamide hydrochloride；4-phenylpiperidine-4-carboxylic acid amide hydrochloric acid salt；4-phenylpiperidine-4-carboxamide hydro-chloride；4-phenylpiperidine-4-carboxamide;hydrochloride
• CAS: 59083-35-1
• 化学式: C₁₂H₁₆N₂O*ClH
• mdl: MFCD00035305
• 分子量: 240.733
• InChiKey: LZWFVOQSFVFPJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.76
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  55.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-苯基哌啶-4-甲酰胺单盐酸盐 在 三溴化硼 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-{5-[(4-Carbamoyl-4-phenylpiperidin-1-yl)carbonyl]-2-(2-chlorophenyl)thien-3-yl}phenyl 3,3,3-trifluoropropane-1-sulphonate
  参考文献：
  名称：

  THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  本发明涉及与式（I）相对应的化合物，其中：R1和R2与它们连接的氮原子一起构成一个饱和的杂环基团，含有4到7个原子，最好是取代的；两个取代基R3和R6中的一个是一个Y-A-R9基团；Y是氧原子或-S(O)n′-或-OSO2基团；A是未取代的（C1-C4）烷基基团；R9是-OR19，-CH3，-NR19R20，-CONR19R20，-NR15COR19，-S(O)nR21或-NR13SO2R21基团；-R10是氢原子或（C1-C4）烷基基团。本发明还涉及制备方法和化合物（I）的治疗用途。

  公开号：

  US20110183960A1
• 作为产物：
  描述：

  1-苄基-4-氰基-4-苯基哌啶盐酸盐 在 palladium 10% on activated carbon 硫酸 、 水 、 1,3-环己二烯 作用下， 以 甲醇 为溶剂， 反应 7.0h， 生成 4-苯基哌啶-4-甲酰胺单盐酸盐
  参考文献：
  名称：

  THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  本发明涉及与式（I）相对应的化合物，其中：R1和R2与它们连接的氮原子一起构成一个饱和的杂环基团，含有4到7个原子，最好是取代的；两个取代基R3和R6中的一个是一个Y-A-R9基团；Y是氧原子或-S(O)n′-或-OSO2基团；A是未取代的（C1-C4）烷基基团；R9是-OR19，-CH3，-NR19R20，-CONR19R20，-NR15COR19，-S(O)nR21或-NR13SO2R21基团；-R10是氢原子或（C1-C4）烷基基团。本发明还涉及制备方法和化合物（I）的治疗用途。

  公开号：

  US20110183960A1

文献信息

• Substituted pyrrolidin-3-yl-alkyl-piperidines
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05635510A1

  公开（公告）日：1997-06-03

  The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.

  本发明涉及取代吡咯啉基-3-基-烷基-哌啶、其立体异构体和药学上可接受的盐以及其制备方法。本发明的化合物在药理活性方面具有用途，如快速激肽拮抗作用，特别是物质P和神经激肽A的拮抗作用等。具有快速激肽拮抗性质的化合物适用于与神经源性炎症和本文所述的其他疾病相关的情况。
• Heterocyclic compounds having tachykinin receptor antagonist activity
  申请人：Sankyo Company, Limited

  公开号：US06159967A1

  公开（公告）日：2000-12-12

  Compounds of the formula and quaternary ammonium ions thereof, wherein R.sup.1 and R.sup.2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4, alkenylene; D is oxygen; E is C.sub.2 alkylene; G is C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4 alkenylene; and L is --C(R.sup.4)(R.sup.5), wherein R.sup.4 and R.sup.5 together with the carbon atom to which they are attached represent a C.sub.5 -C.sub.10 cycloalkyl or a C.sub.5 -C.sub.10 heterocyclic. Especially preferred are compounds wherein L represents ##STR1## wherein J is a C.sub.1 -C.sub.6 alkylene; Ar is a ring carbocyclic or aromatic heterocyclic and S*.fwdarw.O is a sulfoxide in which the sulfur atom is in the 5-configuration. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK.sub.1 and NK.sub.2 receptors.

  式中的化合物及其季铵盐，其中R.sup.1和R.sup.2相同或不同，为碳环芳基或芳香杂环基；A为亚甲基、羰基或砜基；B为单键、C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基；D为氧；E为C.sub.2烷基；G为C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基；L为--C(R.sup.4)(R.sup.5)，其中R.sup.4和R.sup.5与其连接的碳原子一起表示C.sub.5-C.sub.10环烷基或C.sub.5-C.sub.10杂环基。特别优选的是L代表##STR1##其中J为C.sub.1-C.sub.6烷基；Ar为环状碳环或芳香杂环，S*.fwdarw.O为亚砜，其中硫原子处于5-构型。这些化合物具有肽激肽受体拮抗活性，并对NK.sub.1和NK.sub.2受体均表现出活性。
• PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF
  申请人：BARTH Francis

  公开号：US20110144157A1

  公开（公告）日：2011-06-16

  The subject of the invention is Compound of Formula (I): in which R1-R8 and R10 are defined within, its method of preparation, and its therapeutic application.

  本发明的主题是Formula (I)的化合物：其中R1-R8和R10在内部定义，以及其制备方法和治疗应用。
• DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Ducoux Jean-Philippe

  公开号：US20120115906A1

  公开（公告）日：2012-05-10

  The invention relates to compounds of the formula (I), where: R 1 is: a —NR 5 R 6 group; an unsubstituted or substituted phenyl; R 2 is: a (C 1 -C 4 )alkyl; an —X—R 7 group; R 3 and R 4 each are independently a substituted phenyl; R 5 is a hydrogen atom or a (C 1 -C 4 )alkyl; R 6 is an unsubstituted or substituted (C 1 -C 4 )alkyl; or R 5 and R 6 together with the nitrogen atom to which they are bonded constitute an unsubstituted or substituted heterocyclic compound; X is a (C 1 -C 5 )alkylene; R 7 is an —OR 8 group, a —NR 9 R 10 group, an —SO 2 —(C 1 -C 4 )alkyl group; R 8 is a hydrogen atom or a (C 1 -C 4 )alkyl; R 9 is a hydrogen atom or a (C 1 -C 4 )alkyl; R 10 is a hydrogen atom, a —COR 11 group, an —SO 2 R 11 group or a —CO(CH 2 ) m OH group; R 11 is an unsubstituted or substituted (C 1 -C 4 )alkyl; m is 1, 2 or 3. The invention also relates to methods for preparing same and to the therapeutic use thereof.

  该发明涉及公式（I）的化合物，其中：R1是：a-NR5R6基团；未取代或取代的苯基；R2是：（C1-C4）烷基；-X-R7基团；R3和R4各自独立地是取代的苯基；R5是氢原子或（C1-C4）烷基；R6是未取代或取代的（C1-C4）烷基；或R5和R6与它们连接的氮原子一起构成未取代或取代的杂环化合物；X是（C1-C5）烷基；R7是-OR8基团，-NR9R10基团，-SO2-（C1-C4）烷基基团；R8是氢原子或（C1-C4）烷基；R9是氢原子或（C1-C4）烷基；R10是氢原子，-COR11基团，-SO2R11基团或-CO（CH2）mOH基团；R11是未取代或取代的（C1-C4）烷基；m为1、2或3。该发明还涉及制备这些化合物的方法以及它们的治疗用途。
• Method for treating an inflammatory disease
  申请人：Sankyo Company, Limited

  公开号：US06448247B1

  公开（公告）日：2002-09-10

  Compounds of the formula and quaternary ammonium ions thereof, wherein R1 and R2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C1-C4 alkylene or C2-C4 alkenylene; D is oxygen or sulfur; E is C2-C6 alkylene, C1-C6 haloalkylene, C3-C6 cycloalkane-1,1-diyl or C3-C6-cycloalkane-1,1-diylmethyl; G is C1-C4 alkylene or C2-C4 alkenylene; and L is —NR3 or —C(R4)(R5), wherein R3 is a carbocyclic aryl or an aromatic heterocyclic; R4 is hydrogen, carbocyclic aryl or aromatic heterocyclic; R5 is —COR6, C1-C6 alkyl, C1-C6 alkoxy, amino, or acylamino, wherein R6 is C1-C6 alkyl or C1-C6 alkoxy, or R4 and R5 together with the carbon atom to which they are attached represent a C5-C10 cycloalkyl or a C5-C10 heterocyclic. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK1 and NK2 receptors.

  该分子式的化合物及其季铵盐，其中R1和R2相同或不同，为碳环芳基或芳香族杂环；A为亚甲基，羰基或磺酰基；B为单键，C1-C4烷基或C2-C4烯基；D为氧或硫；E为C2-C6烷基，C1-C6卤代烷基，C3-C6环烷-1,1-二基或C3-C6-环烷-1,1-二基甲基；G为C1-C4烷基或C2-C4烯基；L为—NR3或—C（R4）（R5），其中R3为碳环芳基或芳香族杂环；R4为氢，碳环芳基或芳香族杂环；R5为—COR6，C1-C6烷基，C1-C6烷氧基，氨基或酰胺基，其中R6为C1-C6烷基或C1-C6烷氧基，或R4和R5与它们连接的碳原子一起代表C5-C10环烷基或C5-C10杂环。这些化合物具有缓激肽受体拮抗活性，并对NK1和NK2受体均表现出活性。